Guardant Health Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
GH$158.79+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue: | |||
| Precision oncology testing | $514,249 | $392,049 | $304,312 |
| Development services and other | 49,699 | 57,489 | 69,341 |
| Total revenue | 563,948 | 449,538 | 373,653 |
| Costs and operating expenses: | |||
| Cost of precision oncology testing | 205,528 | 148,199 | 110,396 |
| Cost of development services and other | 21,524 | 8,126 | 12,516 |
| Research and development expense | 367,194 | 373,807 | 263,221 |
| Sales and marketing expense | 295,227 | 299,828 | 191,881 |
| General and administrative expense | 155,800 | 163,956 | 206,640 |
| Other operating expense | 83,400 | — | — |
| Total costs and operating expenses | 1,128,673 | 993,916 | 784,654 |
| Loss from operations | (564,725) | (544,378) | (411,001) |
| Interest income | 35,365 | 6,069 | 3,930 |
| Interest expense | (2,578) | (2,577) | (2,577) |
| Other income (expense), net | 53,174 | (12,778) | 25,178 |
| Fair value adjustments of noncontrolling interest liability | — | (99,785) | — |
| Loss before provision for income taxes | (478,764) | (653,449) | (384,470) |
| Provision for income taxes | 685 | 1,139 | 300 |
| Net loss | (479,449) | (654,588) | (384,770) |
| Adjustment of redeemable noncontrolling interest | — | — | (20,900) |
| Net loss attributable to Guardant Health, Inc. common stockholders | $(479,449) | $(654,588) | $(405,670) |
| Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted | $(4.28) | $(6.41) | $(4.00) |
| Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted | 111,988 | 102,178 | 101,314 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.